Genotype | Duration of tamoxifen treatment | |||||
---|---|---|---|---|---|---|
2 years | 5 years | |||||
HR (n) | 95% CI | P | HR (n) | 95% CI | P | |
CYP3A5*1/*1, *1/*3 | 1.00 (16) | 1.00 (13) | ||||
CYP3A5*3/*3 | 2.84 (83) | 0.68–11.99 | 0.15 | 0.20 (95) | 0.07–0.55 | 0.002 |
CYP2D6*1/*1 | 1.00 (72) | 1.00 (79) | ||||
CYP2D6*1/*4, *4/*4 | 0.87 (31) | 0.38–1.97 | 0.74 | 0.33 (32) | 0.08–1.43 | 0.14 |
SULT1A1*1/*2, *2/*2 | 1.00 (71) | 1.00 (73) | ||||
SULT1A1*1/*1 | 0.33 (32) | 0.12–0.96 | 0.04 | 0.83 (36) | 0.29–2.36 | 0.73 |
UGT2B15*1/*1 | 1.00 (17) | 1.00 (26) | ||||
UGT2B15*1/*2, *2/*2 | 1.18 (62) | 0.39–3.52 | 0.77 | 1.94 (55) | 0.53–7.06 | 0.31 |